Abstract
The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Current Pharmaceutical Biotechnology
Title:Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Volume: 13 Issue: 11
Author(s): Natalya Benderska, Saritha Chakilam, Manuela Hugle, Jelena Ivanovska, Muktheshwar Gandesiri, Jan Schulze-Luhrmann, Khuloud Bajbouj, Ronald Croner and Regine Schneider-Stock
Affiliation:
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Abstract: The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Export Options
About this article
Cite this article as:
Benderska Natalya, Chakilam Saritha, Hugle Manuela, Ivanovska Jelena, Gandesiri Muktheshwar, Schulze-Luhrmann Jan, Bajbouj Khuloud, Croner Ronald and Schneider-Stock Regine, Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802501971
DOI https://dx.doi.org/10.2174/138920112802501971 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Immunoliposomes: Synthesis, Structure, and their Potential as Drug Delivery Carriers
Current Cancer Therapy Reviews Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Non-surgical Treatments for Lung Metastases in Patients with Soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)
Current Medical Imaging Electrotransfer as a Non Viral Method of Gene Delivery
Current Gene Therapy Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety The Overlapping Syndromes of the Pick Complex
Current Alzheimer Research Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Current Molecular Pharmacology Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry